NCT04331613View on ClinicalTrials.gov

Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 27, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
COVID-19Acute Respiratory Distress SyndromeVirus; PneumoniaAcute Lung Injury
Interventions
BIOLOGICAL

CAStem

CAStem will be administered intravenously.

Trial Locations (1)

100000

RECRUITING

Beijing YouAn Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
collaborator

Beijing YouAn Hospital

OTHER

lead

Chinese Academy of Sciences

OTHER_GOV